Bill No. 860 amends the Uniform Controlled Dangerous Substances Act in Oklahoma by updating the Schedule I controlled substances list to include new substances such as various opiates, opium derivatives, hallucinogenic substances, and synthetic cannabinoids. This amendment responds to increasing concerns about the abuse and public health risks associated with these substances. Additionally, the bill allows for the exclusion of certain industrial uses of specific substances, like Gamma-Butyrolactone, from being classified as controlled substances, provided they are properly labeled and marketed for legitimate industrial purposes.

The bill introduces new definitions and classifications for synthetic compounds, detailing specific types such as indoles, amides, esters, and ketones, along with examples like CP-47,497 and AM-2233. It also regulates kratom products, aligning them with other controlled substances. Furthermore, the bill clarifies that any FDA-approved prescription drug will not be classified as Schedule I if it is designated, rescheduled, or deleted by the DEA, allowing for its legal prescription under federal law unless the State Board of Pharmacy intervenes. The amendments are set to take effect on November 1, 2025, following Senate passage on March 25, 2025.